Trial Profile
A Phase I Trial of Enzalutamide Plus the Glucocorticoid Receptor Antagonist CORT-125134 (Relacorilant) for Patients With Metastatic Castration Resistant Prostate Cancer (CRPC)
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 09 Jul 2023
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary) ; Relacorilant (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Pharmacokinetics
- 06 Jun 2023 Results (n=35) presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 02 Mar 2023 Planned End Date changed from 10 Mar 2025 to 10 Mar 2026.
- 02 Mar 2023 Planned primary completion date changed from 10 Jan 2023 to 10 Jan 2026.